cd14 af700  (Novus Biologicals)

Journal: iScience

Article Title: Large-scale analysis of cell-cell communication reveals angiogenin-dependent tumor progression in clear cell renal cell carcinoma

doi: 10.1016/j.isci.2023.108367

Figure Lengend Snippet:

Article Snippet: For scRNAseq experiments, the first part of cell suspension was stained with the following antibodies: APC anti-CD45 (BD, 561864, 1:20), BV785 anti-CD3 (Biolegend, 317329, 1:100), PE-CF594 anti-CD11c (BD, 562393, 1:100), FITC anti-CD56 (Biolegend, 318304, 1:50), PerCP-Cy5.5 anti-CD19 (Biolegend, 302230, 1:100), AF700 anti-CD14 (BD, 561029, 1:30), BV421 anti-CD4 (BD, 562425, 1:60).

Techniques: Recombinant, Transfection, Luminex, Software, FCAP Assay

Journal: Veterinary immunology and immunopathology

Article Title: Flow cytometry analysis of CD11c-positive peripheral blood mononuclear cells in horses.

doi: 10.1016/j.vetimm.2022.110504

Figure Lengend Snippet: Fig. 2. Cell immunophenotyping of horse PBMCs using a panel with CD11c, MHC-II, CD14 and TLR4 and cross-reactivity assays. (a) Gate strategy to remove doublets in the forward and side scatter with height to area and cell population identification of population 1 (P1), population 2 (P2) and population 3 (P3). (b) Cell expression dot plot of CD11c+CD14+, CD11c+MHCII+ and CD11c+TLR4+ P1, P2 and P3. (c) Cross-reactivity assay of antibodies for their recognition capacity in equine PBMCs. Black histograms represent the negative control, and colored histograms are representative of P1, P2 and P3. Data representative from one horse. Samples were analyzed by flow cytometry; 50,000 events were obtained. The analysis was performed using FlowJo V10 software.

Article Snippet: The cells were incubated with other surface markers using the following antibodies: anti-horse MHCII-FITC (Batch No. 0515, Bio-Rad), CD14-AF700 (FAB4597N, Novus Biologicals), and TLR4-PE (clone: HTA125, Cat: 312805, Bio-Legend).

Techniques: Expressing, Negative Control, Flow Cytometry, Software

Journal: Journal of Medicinal Chemistry

Article Title: A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia

doi: 10.1021/acs.jmedchem.2c00671

Figure Lengend Snippet: Nilotinib inhibits cell adhesion and monocyte activation. (A) PCA plot of log 2-transformed LFQ intensities from THP-1 cells pre-treated with DMSO, 5 μM nilotinib, or imatinib for 1 h before stimulation with live E. coli for up to 24 h, showing distinct grouping of treatments. (B,C) Volcano plot of THP-1 cells treated with (B) nilotinib vs imatinib and (C) nilotinib vs E. coli , a cutoff of FDR <0.05, and a 1.5-fold change between conditions. (D) Expression levels of CD44, (E) CD11c, (F) CD14, (G) CD49a, and (H) CD54 on the cell surface were measured by flow cytometry. (I) Optical density of dissolved crystal violet was used to evaluate the adhesion rate. Significant differences between two groups were determined by the Mann–Whitney U-test. The statistical significance of the comparisons with E. coli is indicated as follows: ns, not significant; *, P ≤ 0.05; **, P ≤ 0.01. Error bars represent the standard deviation of four biological replicates.

Article Snippet: Cell surface staining was performed by the direct immunofluorescence assay with fluorescent-conjugated antibodies: CD11c-APC (#17-0114-82), CD14-AF700 (#56-0149-42), and CD54-FITC (#11-0541-82) from Thermo Fisher; CD49a-PE (#562115) and CD44-FITC (#338803) from BD Biosciences; and corresponding isotype control antibodies, for 30 min at 4 °C in PBS with 1% FBS, 1% BSA, and 1% human serum (Sigma) to block Fc receptors.

Techniques: Activation Assay, Transformation Assay, Expressing, Flow Cytometry, MANN-WHITNEY, Standard Deviation

Journal: Biomedicines

Article Title: Heat Shock Protein 27 Affects Myeloid Cell Activation and Interaction with Prostate Cancer Cells

doi: 10.3390/biomedicines10092192

Figure Lengend Snippet: Antibodies used for this study .

Article Snippet: CD14 , AF700 , 61D3 , Thermo Fisher Scientific, Dreieich, Germany , 56-0149-42.

Techniques:

Journal: Cell Reports Medicine

Article Title: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

doi: 10.1016/j.xcrm.2022.100603

Figure Lengend Snippet:

Article Snippet: Mouse Anti-Human CD14/AF700 , eBiosciences , 56-0149-42; RRID: AB_2574497.

Techniques: Recombinant, Lysis, Labeling, Software

Journal: International Journal of Molecular Sciences

Article Title: Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS

doi: 10.3390/ijms23063185

Figure Lengend Snippet: Gating strategy for CD4+ and CD8+ Treg populations. Gating strategy for flow cytometric analysis of lymphocyte population to identify CD4+CD25+FoxP3+, CD8+CD25+FoxP3+ and CD8+CD122+Helios+ Tregs. A time gate was initially applied to exclude any electronic noise and artifacts (not shown here). Next, based on size and granularity, lymphocytes were gated in a forward scatter area (FSC-A) versus side scatter area (SSC-A) plot ( A ). Then, doublet cells were excluded using FSC-A/FSC-height (FSC-H), FSC-A/FSC-Width (FSC-W) and SSC-A/SSC-height (SSC-H) parameters ( B ). Next, viable lymphocytes were gated and cells that expressed monocyte, NK cell and B cell lineage markers CD14, CD16 and CD19, respectively were excluded (“dump channel”, dump negative gate) ( C ), followed by expression of CD3 ( D ). CD8+CD122+Helios+ Tregs were identified as CD8+CD122+ cells ( E ) with FoxP3 +/− and Helios co-expression ( F ). CD8+CD25+FoxP3+ Tregs were identified by CD8 and CD25 ( G ) and Foxp3 ( H ) expression. CD4+CD25+FoxP3+ Tregs were identified as CD4 + CD25 + FoxP3 + cells ( I , J ). Representative plots are presented.

Article Snippet: The following fluorochrome-conjugated monoclonal antibodies were used according to the manufacturers’ protocols: CD3-eFluor506 (clone UCHT1; eBioscience, San Diego, CA, USA), CD4-BUV496 (clone SK3; BD Biosciences, San Diego, CA, USA), CD8-APC-eFluor780 (clone RPA-T8; eBioscience), CD122-PerCP-eFluor710 (clone TU27; eBioscience), CD25-BV650 (clone M-A251, BD Biosciences), CD14-AF700 (clone: 61D3; eBioscience), CD16-AF700 (clone: eBioCB16; eBioscience), CD19-AF700 (clone: Hib19; eBioscience), CD152(CTLA-4)-PE (clone 14D3; eBioscience), CD357(GITR)-BV610 (clone 621; BioLegend, San Diego, CA, USA) or PE-eFluor610 (clone eBioAITR; eBioscience), CD279(PD-1)-FITC (clone MIH4; eBioscience), CD62L-PE-eFluor610 (clone MEL-14; eBioscience), CD103-SB780 (clone B-LY7; eBioscience), CD28-eFluor506 (clone CD28.2, eBioscience).

Techniques: Expressing